New hope for MASLD through drug repurposing Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the world’s most common liver disorder, affecting roughly one in three adults. It involves fat buildup in liver cells and is linked to serious liver outcomes and a heightened risk of cardiovascular mortality. A recent study from the University of…